期刊文献+

进展期肺癌肿瘤标记物临床应用价值 被引量:19

Value of CEA,NSE and CYFRA21-1 in Patients with Advanced Lung Carcinoma
下载PDF
导出
摘要 目的 :评价进展期肺癌患者血清癌胚抗原 (CEA)、神经元特异性烯醇化酶 (NSE)、细胞角蛋白19片段 (CYFRA2 1 1)水平在肺癌诊断、确定病理类型和病情评估方面的临床价值。方法 :采用生物素酶免法测定 79例ⅢA、ⅢB、Ⅳ期原发性肺癌和术后复发或转移患者血清CEA、NSE、CYFRA2 1 1水平。结果 :79例进展期肺癌患者治疗前CEA、NSE、CYFRA2 1 1明显高于正常对照组。 3项联合检测阳性率达 97 5 %。鳞癌组、腺癌组和小细胞未分化癌组之间肿瘤标记物水平差异有显著性。CEA水平以腺癌组最高 ,NSE水平以小细胞未分化癌组最高 ,CYFRA2 1 1水平以鳞癌组最高。化疗有效者肿瘤标记物水平降低 ,病情进展和肿瘤转移患者则升高。结论 :CEA、NSE、CYFRA2 1 1联合用于肺癌的诊断有极高的特异性和敏感性 ,NSE CYFRA2 1 1与肺癌的病理类型有很好的相关性 ,为无法做病理学检查的患者的治疗提供支持 。 Objective To evaluate the value of CEA,NSE and CYFRA21 1 in patients with advanced lung carcinoma.Methods These tumor markers in serum were measured in 79 patients with advanced lung carcinoma using biotin strepavidin EIA.Results The level of CEA,NSE and CYFRA21 1 in patients with advanced lung carcinoma before treatment was significantly higher than that in controls.Single analysis showed that CEA for adenocarcinoma,NSE for small cell lung cancer and CYFRA21 1 for squamous carcinoma had higher positive rate.Combination of these tumor markers increased sensitivity.After chemotherapy (curative effects:CR PR),the serum levels of the markers in patients with object remission was decreased significantly.Conclusions Measurement of CEA,NSE and CYFRA21 1 in serum provides useful information for diagnosis and evaluation of disease extent in patients with advanced lung cancer.The ratio of NSE to CYFRA21 1 is a wonderful index correlated to the pathologic type.The changement of biomarkers serum level reflects the effects of chemotherapy. China J Cancer Prev Treat,2003,10(3):272-275
出处 《肿瘤防治杂志》 2003年第3期272-275,共4页 China Journal of Cancer Prevention and Treatment
关键词 肺肿瘤/诊断 磷酸丙酮酸水合酶/血液 癌胚抗原/血液 角蛋白/血液 肿瘤标记 生物学 lung neoplasms/diagnosis phosphopyruvate hydratase/blood carcinoembryonic antigen/blood keratin/blood tumor markers,biology
  • 相关文献

参考文献7

  • 1[1]Cooper EH.Neuron-specific enolase[J].Int J Biol Markers,1994,9(4):205-210.
  • 2[2]Niklinski J,Furman M,Chyczewska E,et al.Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer[J].Eur Respir J,1995,8(2):291-294.
  • 3[3]Maeda Y,Segawa Y,Takigawa N,et al.Clinical usefulness of serum cytokeratin 19 fragment as a tumor marker for lung cancer[J].Intern Med,1996,35(10):764-771.
  • 4[4]Mitsuhashi N,Takahashi T,Sakurai H,et al.Establishment and characterization of a new human lung poorly differentiated adenocarcinoma cell line,GLL-1,producing carcinoembryonic antigen (CEA) and CA19-9[J].Lung Cancer,1995,12(1-2):13-24.
  • 5[5]Diez M,Gomez A,Hernando F,et al.Serum CEA,CA125,and SCC antigens and tumor recurrence in resectable non-small cell lung cancer[J].Int J Biol Markers,1995,10(1):5-10.
  • 6[6]Pujol JL,Grenier J,Parrat E,et al.Cytokeratins as serum markers in lung cancer:a comparison of CYFRA 21-1 and TPS[J].Am J Respir Crit Care Med, 1996,154(3 Pt 1):725-733.
  • 7[7]Van de Pol M,Twijnstra A,ten Velde GP,et al.Neuron-specific enolase as a marker of brain metastasis in patients with small-cell lung carcinoma[J].J Neurooncol,1994,19(2):149-154.

同被引文献121

引证文献19

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部